Frank Vinluan

October 24th, 2019

• @frankvinluan
• @xconomy
• Like Us

Xconomy Boston — 

Akcea Therapeutics (NASDAQ: AKCA) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a treatment for the nerves damage caused by the rare disease hereditary transthyretin amyloidosis.